Page last updated: 2024-11-13

gs-9620

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID46241268
CHEMBL ID2424780
SCHEMBL ID10083191
MeSH IDM0586577

Synonyms (48)

Synonym
gs 9620
vesatolimod [usan:inn]
4-amino-2-butoxy-8-(3-(1-pyrrolidinylmethyl)benzyl)-7,8-dihydro-6(5h)-pteridinone
vesatolimod
vesatolimod [inn]
1228585-88-3
6(5h)-pteridinone, 4-amino-2-butoxy-7,8-dihydro-8-((3-(1-pyrrolidinylmethyl)phenyl)methyl)-
gs9620
o8m467c50g ,
gs-9620 ,
unii-o8m467c50g
HY-15601
CS-1352
4-amino-2-butoxy-8-({3-[(pyrrolidin-1-yl)methyl]phenyl}methyl)-7,8-dihydropteridin-6(5h)-one
vesatolimod [who-dd]
vesatolimod [usan]
S7221
chembl2424780 ,
bdbm50440284
SCHEMBL10083191
AKOS025290740
8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5h)-one
AC-30275
DTXSID40153741
4-amino-2-butoxy-8-({3-[(pyrrolidin-1-yl)methyl]phenyl}methyl)-5,6,7,8-tetrahydropteridin-6-one
AS-74316
D11003
vesatolimod (usan/inn)
mfcd25372045
NCGC00390283-03
VFOKSTCIRGDTBR-UHFFFAOYSA-N
4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5h)-one
4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one
DB12687
FT-0721305
BCP08305
9jr ,
4-azanyl-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one
SB16757
4-amino-2-butoxy-7,8-dihydro-8-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-6(5h)-pteridinone
AMY41043
HMS3750I03
CCG-268776
EX-A2065
Q27285487
NCGC00390283-02
NCGC00390283-01
SY028554

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Minimal treatment-related adverse events were seen at doses up to 8 mg."( Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Frey, CR; Hesselgesser, J; Kearney, B; Lopatin, U; McHutchison, JG; Moorehead, L; Ohmstede, C; Subramanian, GM; Tumas, D; Wolfgang, G, 2013
)
0.64
" Pharmacodynamic activity is seen before adverse events, suggesting the potential for induction of an antiviral response without systemic adverse events in subjects with chronic viral hepatitis."( Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Frey, CR; Hesselgesser, J; Kearney, B; Lopatin, U; McHutchison, JG; Moorehead, L; Ohmstede, C; Subramanian, GM; Tumas, D; Wolfgang, G, 2013
)
0.64
" In healthy volunteers, low doses of GS-9620 (2, 4 and 6 mg) induced significant expression of peripheral interferon-stimulated-gene (ISG) mRNA in the absence of detectable serum interferon-α and systemic adverse events (AEs)."( Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Freilich, B; Gaggar, A; Gruener, D; Hassman, D; Hill, J; Jacobson, IM; Lawitz, E; Marbury, T; Massetto, B; McHutchison, JG; Mogalian, E; Nguyen, AH; Pflanz, S; Rodriguez-Torres, M; Subramanian, GM; Webster, L, 2015
)
0.91
"Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms."( Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Ahn, SH; Brunetto, MR; Ferrari, C; Fung, S; Gaggar, A; Gane, EJ; Janssen, HLA; Joshi, A; Kim, YJ; Lau, AH; Massetto, B; Nguyen, AH; Subramanian, GM; Tsai, NCS; Woo, J; Yoshida, EM, 2018
)
0.73
"In a phase II study, vesatolimod, an oral, once-weekly, experimental immune-activating drug for the treatment of hepatitis B virus (HBV), is safe and well-tolerated in chronic HBV patients who are virally suppressed on oral antiviral treatment."( Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Ahn, SH; Brunetto, MR; Ferrari, C; Fung, S; Gaggar, A; Gane, EJ; Janssen, HLA; Joshi, A; Kim, YJ; Lau, AH; Massetto, B; Nguyen, AH; Subramanian, GM; Tsai, NCS; Woo, J; Yoshida, EM, 2018
)
0.73
"1%) experienced ≥1 treatment-emergent adverse event; the majority were mild or moderate in severity."( Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
Agarwal, K; Ahn, SH; Andreone, P; Bulusu, A; Cathcart, AL; Chuang, WL; Elkhashab, M; Gaggar, A; Kim, HJ; Lau, AH; Nguyen, MH; Subramanian, GM; Tian, X; Woo, J, 2018
)
0.76

Pharmacokinetics

GS-9620 exhibited dose-linear pharmacokinetics with a median half-life in plasma of 18 h. It induces the production of select chemokines and cytokines, including IFN-α and interferon-stimulated genes (ISGs)

ExcerptReferenceRelevance
"GS-9620 demonstrates safety and pharmacodynamic activity at doses up to 12 mg."( Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Frey, CR; Hesselgesser, J; Kearney, B; Lopatin, U; McHutchison, JG; Moorehead, L; Ohmstede, C; Subramanian, GM; Tumas, D; Wolfgang, G, 2013
)
2.09
" We characterized the pharmacodynamic response of GS-9620 in CD-1 mice and cynomolgus monkeys following intravenous or oral administration and showed that GS-9620 induces the production of select chemokines and cytokines, including IFN-α and interferon-stimulated genes (ISGs)."( Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.
Fosdick, A; Frey, CR; Halcomb, RL; Hesselgesser, J; Pflanz, S; Tumas, DB; Wolfgang, G; Zheng, J, 2014
)
0.91
" Pharmacodynamic assessments included peripheral ISG15 mRNA expression, serum interferon-α and interferon-γ-inducible protein (IP)-10 levels and HCV RNA quantification."( Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Freilich, B; Gaggar, A; Gruener, D; Hassman, D; Hill, J; Jacobson, IM; Lawitz, E; Marbury, T; Massetto, B; McHutchison, JG; Mogalian, E; Nguyen, AH; Pflanz, S; Rodriguez-Torres, M; Subramanian, GM; Webster, L, 2015
)
0.64
"Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFNα expression or related symptoms."( Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Ahn, SH; Brunetto, MR; Ferrari, C; Fung, S; Gaggar, A; Gane, EJ; Janssen, HLA; Joshi, A; Kim, YJ; Lau, AH; Massetto, B; Nguyen, AH; Subramanian, GM; Tsai, NCS; Woo, J; Yoshida, EM, 2018
)
0.73

Bioavailability

ExcerptReferenceRelevance
"GS-9620 [8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one] is a potent, orally bioavailable small-molecule agonist of Toll-like receptor 7 (TLR7) developed for finite treatment of chronic hepatitis B viral (HBV) infection, with the goal of inducing a liver-targeted antiviral effect without inducing the adverse effects associated with current systemic interferon-α (IFN-α) therapies."( Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.
Fosdick, A; Frey, CR; Halcomb, RL; Hesselgesser, J; Pflanz, S; Tumas, DB; Wolfgang, G; Zheng, J, 2014
)
2.1
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"After evaluating the pharmacokinetics, pharmacodynamics and tolerability of oral GS-9620 in uninfected woodchucks, adult woodchucks chronically infected with WHV (n = 7 per group) were dosed with GS-9620 or placebo for 4 or 8 weeks with different treatment schedules."( Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.
AlDeghaither, D; Baldwin, BH; Bellezza, CA; Cote, PJ; Daffis, S; Fletcher, SP; Fosdick, A; Halcomb, R; Li, L; Liu, KH; Menne, S; Tennant, BC; Thampi, L; Tumas, DB; Wolfgang, GH; Yue, P; Zheng, J, 2015
)
0.87
" Overall, a transient dose-dependent induction of peripheral ISG15 gene expression was observed peaking within 48 hours of dosing followed by return to baseline levels within seven days."( The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Cheng, W; Coffin, CS; Fedorak, RN; Freilich, B; Gaggar, A; Gane, EJ; Garrison, KL; Gordon, SC; Kim, YJ; Kottilil, S; Lim, YS; Mani Subramanian, G; Massetto, B; McHutchison, JG; Pflanz, S; Roberts, S; Sicard, E; Visvanathan, K; Ye, Z, 2015
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency15.09160.01237.983543.2770AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency3.37860.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Toll-like receptor 8Homo sapiens (human)EC50 (µMol)9.00000.48004.26369.0000AID770386
Toll-like receptor 7Homo sapiens (human)EC50 (µMol)0.29000.00721.57446.8000AID770387
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Toll-like receptor 8Homo sapiens (human)MEC3.65000.08001.35173.6500AID770389
Toll-like receptor 7Homo sapiens (human)MEC0.00300.00300.06570.1000AID770391
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
regulation of protein phosphorylationToll-like receptor 8Homo sapiens (human)
inflammatory responseToll-like receptor 8Homo sapiens (human)
response to virusToll-like receptor 8Homo sapiens (human)
immunoglobulin mediated immune responseToll-like receptor 8Homo sapiens (human)
negative regulation of interleukin-12 productionToll-like receptor 8Homo sapiens (human)
positive regulation of interferon-alpha productionToll-like receptor 8Homo sapiens (human)
positive regulation of interferon-beta productionToll-like receptor 8Homo sapiens (human)
positive regulation of type II interferon productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-1 beta productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-6 productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 8Homo sapiens (human)
toll-like receptor 8 signaling pathwayToll-like receptor 8Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionToll-like receptor 8Homo sapiens (human)
innate immune responseToll-like receptor 8Homo sapiens (human)
positive regulation of innate immune responseToll-like receptor 8Homo sapiens (human)
defense response to virusToll-like receptor 8Homo sapiens (human)
cellular response to mechanical stimulusToll-like receptor 8Homo sapiens (human)
toll-like receptor signaling pathwayToll-like receptor 8Homo sapiens (human)
canonical NF-kappaB signal transductionToll-like receptor 8Homo sapiens (human)
regulation of protein phosphorylationToll-like receptor 7Homo sapiens (human)
inflammatory responseToll-like receptor 7Homo sapiens (human)
canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
I-kappaB phosphorylationToll-like receptor 7Homo sapiens (human)
JNK cascadeToll-like receptor 7Homo sapiens (human)
positive regulation of chemokine productionToll-like receptor 7Homo sapiens (human)
positive regulation of interferon-alpha productionToll-like receptor 7Homo sapiens (human)
positive regulation of interferon-beta productionToll-like receptor 7Homo sapiens (human)
positive regulation of type II interferon productionToll-like receptor 7Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 7Homo sapiens (human)
toll-like receptor 7 signaling pathwayToll-like receptor 7Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
innate immune responseToll-like receptor 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIToll-like receptor 7Homo sapiens (human)
positive regulation of inflammatory responseToll-like receptor 7Homo sapiens (human)
defense response to virusToll-like receptor 7Homo sapiens (human)
positive regulation of macrophage cytokine productionToll-like receptor 7Homo sapiens (human)
response to cGMPToll-like receptor 7Homo sapiens (human)
cellular response to mechanical stimulusToll-like receptor 7Homo sapiens (human)
cellular response to virusToll-like receptor 7Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
toll-like receptor signaling pathwayToll-like receptor 7Homo sapiens (human)
positive regulation of interleukin-6 productionToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
DNA bindingToll-like receptor 8Homo sapiens (human)
RNA bindingToll-like receptor 8Homo sapiens (human)
double-stranded RNA bindingToll-like receptor 8Homo sapiens (human)
single-stranded RNA bindingToll-like receptor 8Homo sapiens (human)
signaling receptor activityToll-like receptor 8Homo sapiens (human)
pattern recognition receptor activityToll-like receptor 8Homo sapiens (human)
double-stranded RNA bindingToll-like receptor 7Homo sapiens (human)
single-stranded RNA bindingToll-like receptor 7Homo sapiens (human)
protein bindingToll-like receptor 7Homo sapiens (human)
siRNA bindingToll-like receptor 7Homo sapiens (human)
pattern recognition receptor activityToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
Golgi membraneToll-like receptor 8Homo sapiens (human)
endoplasmic reticulum membraneToll-like receptor 8Homo sapiens (human)
external side of plasma membraneToll-like receptor 8Homo sapiens (human)
endosome membraneToll-like receptor 8Homo sapiens (human)
endolysosome membraneToll-like receptor 8Homo sapiens (human)
plasma membraneToll-like receptor 8Homo sapiens (human)
Golgi membraneToll-like receptor 7Homo sapiens (human)
cytoplasmToll-like receptor 7Homo sapiens (human)
lysosomeToll-like receptor 7Homo sapiens (human)
endosomeToll-like receptor 7Homo sapiens (human)
endoplasmic reticulumToll-like receptor 7Homo sapiens (human)
endoplasmic reticulum membraneToll-like receptor 7Homo sapiens (human)
plasma membraneToll-like receptor 7Homo sapiens (human)
endosome membraneToll-like receptor 7Homo sapiens (human)
early phagosomeToll-like receptor 7Homo sapiens (human)
endolysosome membraneToll-like receptor 7Homo sapiens (human)
receptor complexToll-like receptor 7Homo sapiens (human)
plasma membraneToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID770386Agonist activity at human TLR8 expressed in HEK293 cells by reporter based assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770381Half life in human liver microsomes2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770365Agonist activity at THR8 in cynomolgus monkey assessed as increase of serum IFNalpha level at 2 mg/kg after 1 to 24 hrs by ELISA2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770375Cmax in cynomolgus monkey at 0.3 mg/kg, po2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770391Agonist activity at TLR7-mediated IFNalpha production in human PBMC assessed as minimum concentration of compound necessary to generate >3 fold of cytokine levels relative to control2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770387Agonist activity at human TLR7 expressed in HEK293 cells by reporter based assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770368Agonist activity at THR7 in cynomolgus monkey assessed as increase of serum IFNalpha level at 2 mg/kg, po after 1 to 24 hrs by ELISA2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770380Clearance in cynomolgus monkey at 0.1 mg/kg, iv and 0.3 mg/kg, po2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770382Half life in dog liver microsomes2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770378Oral bioavailability in cynomolgus monkey at 0.3 mg/kg2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770372Agonist activity at THR7 in cynomolgus monkey assessed as increase of serum IFNalpha level at 0.1 mg/kg, iv after 1 to 24 hrs by ELISA2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770367Agonist activity at THR7 in po dosed cynomolgus monkey assessed as increase of serum IFNalpha level after 1 to 24 hrs by ELISA2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID1373566Selectivity index, ratio of MEC for agonist activity at human TLR8 expressed in HEK293 cells to MEC for agonist activity at human TLR7 expressed in HEK293 cells as2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.
AID770379Volume of distribution at steady state in cynomolgus monkey at 0.1 mg/kg, iv and 0.3 mg/kg, po2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770389Agonist activity at TLR8-mediated TNFalpha production in human PBMC assessed as minimum concentration of compound necessary to generate >3 fold of cytokine levels relative to control2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770370Agonist activity at THR7 in cynomolgus monkey assessed as increase of serum IFNalpha level at 0.3 mg/kg, po after 1 to 24 hrs by ELISA2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770373Cmax in cynomolgus monkey at 1 mg/kg, po2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770377Cmax in cynomolgus monkey at 0.1 mg/kg, iv2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770390Selectivity ratio of MEC for TLR8-mediated TNFalpha production in human PBMC to MEC for TLR7-mediated IFNalpha production in human PBMC2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770384Half life in rat liver microsomes2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770371Agonist activity at THR7 in cynomolgus monkey assessed as increase of serum IFNalpha level at 0.1 mg/kg, po after 1 to 24 hrs by ELISA2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770376Cmax in cynomolgus monkey at 0.1 mg/kg, po2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770366Agonist activity at THR8 in cynomolgus monkey assessed as increase of serum IFNalpha level at 0.3 to 1 mg/kg after 1 to 24 hrs by ELISA2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770369Agonist activity at THR7 in cynomolgus monkey assessed as increase of serum IFNalpha level at 1 mg/kg, po after 1 to 24 hrs by ELISA2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770383Half life in monkey liver microsomes2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770385Half life in mouse liver microsomes2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
AID770374Cmax in cynomolgus monkey at 2 mg/kg, po2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's32 (69.57)24.3611
2020's14 (30.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.29 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index28.85 (26.88)
Search Engine Supply Index1.78 (0.95)

This Compound (28.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (19.57%)5.53%
Reviews4 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (71.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]